Don't be alarmed if osteoporosis drugs designed to improve your bone-mineal density (BMD) don't do so the first year that you take them. By year two, they probably will. Researchers analyzing data from studies involving more than 10,000 women who took alendronate (Fosamax) or raloxifene (Evista) found that a very small percentage of the women appeared to lose BMD over the first year. But 92 percent of the alendronate group and 79 percent of those treated with raloxifene showed gains during the second year.
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment